{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T11:50:11Z","timestamp":1781265011845,"version":"3.54.1"},"reference-count":61,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,30]],"date-time":"2022-05-30T00:00:00Z","timestamp":1653868800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ackdjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Chronic Kidney Disease"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1053\/j.ackd.2022.05.002","type":"journal-article","created":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T17:45:34Z","timestamp":1664214334000},"page":"329-336","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Importance of Metabolic Acidosis as a Health Risk in Chronic Kidney Disease"],"prefix":"10.1053","volume":"29","author":[{"given":"Anita","family":"Vincent-Johnson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1707-691X","authenticated-orcid":false,"given":"Julia J.","family":"Scialla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1053\/j.ackd.2022.05.002_bib1","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1053\/j.ackd.2012.11.001","article-title":"Dietary acid load: a novel nutritional target in chronic kidney disease?","volume":"20","author":"Scialla","year":"2013","journal-title":"Adv Chronic Kidney Dis"},{"issue":"2","key":"10.1053\/j.ackd.2022.05.002_bib2","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3945\/ajcn.2009.28637","article-title":"Estimation of the diet-dependent net acid load in 229 worldwide historically studied hunter-gatherer societies","volume":"91","author":"Str\u00f6hle","year":"2009","journal-title":"Am J Clin Nutr"},{"issue":"4","key":"10.1053\/j.ackd.2022.05.002_bib3","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.semnephrol.2019.04.008","article-title":"Emerging Features of ammonia metabolism and Transport in acid-base balance","volume":"39","author":"Weiner","year":"2019","journal-title":"Semin Nephrol"},{"issue":"12","key":"10.1053\/j.ackd.2022.05.002_bib4","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.2215\/CJN.07400715","article-title":"Acid-base homeostasis","volume":"10","author":"Hamm","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ackd.2022.05.002_bib5","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1681\/ASN.2008020159","article-title":"Timing of Onset of CKD-related metabolic complications","volume":"20","author":"Moranne","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ackd.2022.05.002_bib6","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1111\/j.1523-1755.2004.00481.x","article-title":"Prevalence of acidosis and inflammation and their association with low serum albumin in chronic kidney disease","volume":"65","author":"Eustace","year":"2004","journal-title":"Kidney Int"},{"issue":"12","key":"10.1053\/j.ackd.2022.05.002_bib7","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1681\/ASN.2010111181","article-title":"Estimated GFR, albuminuria, and complications of chronic kidney disease","volume":"22","author":"Inker","year":"2011","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.ackd.2022.05.002_bib8","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1053\/j.ajkd.2018.08.013","article-title":"Relationship of estimated GFR and albuminuria to concurrent laboratory abnormalities: an individual participant data meta-analysis in a Global Consortium","volume":"73","author":"Inker","year":"2019","journal-title":"Am J Kidney Dis"},{"issue":"19","key":"10.1053\/j.ackd.2022.05.002_bib9","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"issue":"9811","key":"10.1053\/j.ackd.2022.05.002_bib10","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0140-6736(11)60178-5","article-title":"Chronic kidney disease","volume":"379","author":"Levey","year":"2012","journal-title":"Lancet"},{"issue":"2","key":"10.1053\/j.ackd.2022.05.002_bib11","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1053\/j.ajkd.2009.02.014","article-title":"Serum bicarbonate levels and the progression of kidney disease: a cohort study","volume":"54","author":"Shah","year":"2009","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"10.1053\/j.ackd.2022.05.002_bib12","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.2215\/CJN.00070109","article-title":"Chronic Renal Insufficiency Cohort (CRIC) Study: baseline characteristics and associations with kidney function","volume":"4","author":"Lash","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ackd.2022.05.002_bib13","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1365-2753.2008.00965.x","article-title":"Chronic kidney disease: appropriateness of therapeutic management and associated factors in the AVENIR study","volume":"15","author":"Thilly","year":"2009","journal-title":"J Eval Clin Pract"},{"issue":"2","key":"10.1053\/j.ackd.2022.05.002_bib14","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s12325-020-01587-5","article-title":"Renal tubular acidosis and management Strategies: a Narrative review","volume":"38","author":"Palmer","year":"2021","journal-title":"Adv Ther"},{"issue":"8","key":"10.1053\/j.ackd.2022.05.002_bib15","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1097\/01.ASN.0000023430.92674.E5","article-title":"Renal tubular acidosis: the clinical Entity","volume":"13","author":"Rodr\u00edguez Soriano","year":"2002","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ackd.2022.05.002_bib16","doi-asserted-by":"crossref","first-page":"608","DOI":"10.34067\/KID.0006802021","article-title":"Hyperkalemia and metabolic acidosis occur at higher estimated glomerular filtration rates in sickle cell disease","volume":"3","author":"Saraf","year":"2022","journal-title":"Kidney360"},{"issue":"12","key":"10.1053\/j.ackd.2022.05.002_bib17","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1007\/s00296-018-4118-x","article-title":"Renal involvement in primary Sjogren\u2019s syndrome: a prospective cohort study","volume":"38","author":"Jain","year":"2018","journal-title":"Rheumatol Int"},{"issue":"9","key":"10.1053\/j.ackd.2022.05.002_bib18","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.2215\/CJN.00980209","article-title":"Renal involvement in primary Sj\u00f6gren's syndrome: a Clinicopathologic study","volume":"4","author":"Maripuri","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ackd.2022.05.002_bib19","doi-asserted-by":"crossref","first-page":"16","DOI":"10.2215\/CJN.07830719","article-title":"Tubular acidification Defect in adults with sickle cell disease","volume":"15","author":"Cazenave","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ackd.2022.05.002_bib20","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1053\/j.ajkd.2013.01.017","article-title":"Association of serum bicarbonate with risk of renal and cardiovascular outcomes in CKD: a report from the Chronic Renal Insufficiency Cohort (CRIC) study","volume":"62","author":"Dobre","year":"2013","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1053\/j.ackd.2022.05.002_bib21","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.semnephrol.2004.06.014","article-title":"Cellular mechanisms causing loss of muscle mass in kidney disease","volume":"24","author":"Mitch","year":"2004","journal-title":"Semin Nephrol"},{"issue":"5","key":"10.1053\/j.ackd.2022.05.002_bib22","doi-asserted-by":"crossref","first-page":"714","DOI":"10.2215\/CJN.08340812","article-title":"Effects of oral sodium bicarbonate in patients with CKD","volume":"8","author":"Abramowitz","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"10.1053\/j.ackd.2022.05.002_bib23","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1681\/ASN.2008111205","article-title":"Bicarbonate supplementation slows progression of CKD and improves nutritional status","volume":"20","author":"de Brito-Ashurst","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ackd.2022.05.002_bib24","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/ndt\/gfy214","article-title":"Correction of metabolic acidosis improves muscle mass and renal function in chronic kidney disease stages 3 and 4: a randomized controlled trial","volume":"35","author":"Dubey","year":"2020","journal-title":"Nephrol Dial Transplant"},{"issue":"27","key":"10.1053\/j.ackd.2022.05.002_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta24270","article-title":"Sodium bicarbonate to improve physical function in patients over 60 years with advanced chronic kidney disease: the BiCARB RCT","volume":"24","author":"Witham","year":"2020","journal-title":"Health Technol Assess"},{"issue":"2","key":"10.1053\/j.ackd.2022.05.002_bib26","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1053\/j.ajkd.2019.07.016","article-title":"Effects of sodium bicarbonate in CKD stages 3 and 4: a randomized, placebo-controlled, multicenter clinical trial","volume":"75","author":"Melamed","year":"2020","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1053\/j.ackd.2022.05.002_bib27","doi-asserted-by":"crossref","first-page":"666","DOI":"10.34067\/KID.0005402021","article-title":"Longitudinal associations between low serum bicarbonate and linear growth in children with chronic kidney disease","volume":"3","author":"Brown","year":"2022","journal-title":"Kidney360"},{"issue":"8","key":"10.1053\/j.ackd.2022.05.002_bib28","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1007\/s00467-009-1169-y","article-title":"Bicarbonate therapy improves growth in children with incomplete distal renal tubular acidosis","volume":"24","author":"Sharma","year":"2009","journal-title":"Pediatr Nephrol"},{"issue":"11","key":"10.1053\/j.ackd.2022.05.002_bib29","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1681\/ASN.2011040414","article-title":"Effects of pH on potassium: new explanations for old observations","volume":"22","author":"Aronson","year":"2011","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ackd.2022.05.002_bib30","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1681\/ASN.2019030287","article-title":"A randomized trial comparing the safety, Adherence, and Pharmacodynamics Profiles of Two doses of sodium bicarbonate in CKD: the BASE Pilot trial","volume":"31","author":"Raphael","year":"2020","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ackd.2022.05.002_bib31","first-page":"1","article-title":"Correction of chronic metabolic acidosis for chronic kidney disease patients","author":"Roderick","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1053\/j.ackd.2022.05.002_bib32","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1681\/ASN.2019070677","article-title":"Mechanisms of metabolic acidosis\u2013induced kidney injury in chronic kidney disease","volume":"31","author":"Wesson","year":"2020","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.ackd.2022.05.002_bib33","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1172\/JCI112020","article-title":"Pathophysiology of chronic tubulo-interstitial disease in rats. Interactions of dietary acid load, ammonia, and complement component C3","volume":"76","author":"Nath","year":"1985","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1053\/j.ackd.2022.05.002_bib34","doi-asserted-by":"crossref","first-page":"F830","DOI":"10.1152\/ajprenal.00587.2010","article-title":"Acid retention accompanies\u00a0reduced GFR in humans and increases plasma levels of endothelin and aldosterone","volume":"300","author":"Wesson","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"issue":"10","key":"10.1053\/j.ackd.2022.05.002_bib35","first-page":"1463","article-title":"Effect of treatment of metabolic acidosis on vascular endothelial function in patients with CKD","volume":"13","author":"Kendrick","year":"2018","journal-title":"A Pilot Randomized Cross-Over Study"},{"issue":"6","key":"10.1053\/j.ackd.2022.05.002_bib36","doi-asserted-by":"crossref","first-page":"755","DOI":"10.2215\/CJN.07060619","article-title":"Low serum bicarbonate and CKD progression in children","volume":"15","author":"Brown","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ackd.2022.05.002_bib37","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/ki.2010.388","article-title":"Higher serum bicarbonate levels within the normal range are associated with better survival and renal outcomes in African Americans","volume":"79","author":"Raphael","year":"2011","journal-title":"Kidney Int"},{"issue":"5","key":"10.1053\/j.ackd.2022.05.002_bib38","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1053\/j.ajkd.2021.03.026","article-title":"The Promise of tubule Biomarkers in kidney disease: a review","volume":"78","author":"Ix","year":"2021","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1053\/j.ackd.2022.05.002_bib39","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s40620-019-00656-5","article-title":"Treatment of metabolic acidosis with sodium bicarbonate delays progression of chronic kidney disease: the UBI Study","volume":"32","author":"Di Iorio","year":"2019","journal-title":"J Nephrol"},{"issue":"7","key":"10.1053\/j.ackd.2022.05.002_bib40","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/ki.2009.519","article-title":"Amelioration of metabolic acidosis in patients with low GFR reduced kidney endothelin production and kidney injury, and better preserved GFR","volume":"77","author":"Phisitkul","year":"2010","journal-title":"Kidney Int"},{"issue":"10141","key":"10.1053\/j.ackd.2022.05.002_bib41","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)31080-8","article-title":"Sodium bicarbonate therapy for patients with severe metabolic acidaemia in the intensive care unit (BICAR-ICU): a multicentre, open-label, randomised controlled, phase 3 trial","volume":"392","author":"Jaber","year":"2018","journal-title":"Lancet"},{"issue":"9","key":"10.1053\/j.ackd.2022.05.002_bib42","doi-asserted-by":"crossref","first-page":"e030596","DOI":"10.1136\/bmjopen-2019-030596","article-title":"Effects of antihypertensives, lipid-modifying drugs, glycaemic control drugs and sodium bicarbonate on the progression of stages 3 and 4 chronic kidney disease in adults: a systematic review and meta-analysis","volume":"9","author":"Taylor","year":"2019","journal-title":"BMJ Open"},{"issue":"2","key":"10.1053\/j.ackd.2022.05.002_bib43","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3390\/jcm8020208","article-title":"Oral bicarbonate therapy in non-haemodialysis dependent chronic kidney disease patients: a systematic review and meta-analysis of randomised controlled trials","volume":"8","author":"Hu","year":"2019","journal-title":"J Clin Med"},{"issue":"7","key":"10.1053\/j.ackd.2022.05.002_bib44","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.2215\/CJN.13091118","article-title":"Effects of treatment of metabolic acidosis in CKD: a systematic review and meta-analysis","volume":"14","author":"Navaneethan","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ackd.2022.05.002_bib45","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.ekir.2020.12.019","article-title":"A systematic review and meta-analysis on effects of bicarbonate therapy on kidney outcomes","volume":"6","author":"Hultin","year":"2021","journal-title":"Kidney Int Rep"},{"issue":"6 Suppl 2","key":"10.1053\/j.ackd.2022.05.002_bib46","first-page":"S1","article-title":"Clinical practice guidelines for nutrition in chronic renal failure","volume":"35","year":"2000","journal-title":"Am J Kidney Dis"},{"issue":"4 Suppl 3","key":"10.1053\/j.ackd.2022.05.002_bib47","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease","volume":"42","year":"2003","journal-title":"Am J Kidney Dis"},{"issue":"2 Suppl 1","key":"10.1053\/j.ackd.2022.05.002_bib48","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"39","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2022.05.002_bib49","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.ajkd.2005.07.028","article-title":"K\/DOQI clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease: Work group Membership","volume":"46","year":"2005","journal-title":"Am J Kidney Dis"},{"issue":"3 Suppl 2","key":"10.1053\/j.ackd.2022.05.002_bib50","first-page":"S11","article-title":"KDOQI clinical practice guideline for nutrition in children with CKD: 2008 update. Executive summary","volume":"53","year":"2009","journal-title":"Am J Kidney Dis"},{"issue":"113","key":"10.1053\/j.ackd.2022.05.002_bib51","first-page":"S1","article-title":"KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)","year":"2009","journal-title":"Kidney Int Suppl"},{"issue":"1","key":"10.1053\/j.ackd.2022.05.002_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.kisu.2017.04.001","article-title":"KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)","volume":"7","year":"2017","journal-title":"Kidney Int Suppl (2011)"},{"issue":"1","key":"10.1053\/j.ackd.2022.05.002_bib53","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","year":"2013","journal-title":"Kidney Int Suppl"},{"issue":"5","key":"10.1053\/j.ackd.2022.05.002_bib54","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1053\/j.ajkd.2014.01.416","article-title":"KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD","volume":"63","author":"Inker","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"3, Supplement 1","key":"10.1053\/j.ackd.2022.05.002_bib55","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/j.ajkd.2020.05.006","article-title":"KDOQI clinical practice guideline for nutrition in CKD: 2020 update","volume":"76","author":"Ikizler","year":"2020","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1053\/j.ackd.2022.05.002_bib56","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12916-020-01542-9","article-title":"Clinical and cost-effectiveness of oral sodium bicarbonate therapy for older patients with chronic kidney disease and low-grade acidosis (BiCARB): a pragmatic randomised, double-blind, placebo-controlled trial","volume":"18","year":"2020","journal-title":"BMC Med"},{"issue":"15","key":"10.1053\/j.ackd.2022.05.002_bib57","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1001\/jama.2011.451","article-title":"A predictive Model for progression of chronic kidney disease to kidney failure","volume":"305","author":"Tangri","year":"2011","journal-title":"JAMA"},{"issue":"27","key":"10.1053\/j.ackd.2022.05.002_bib58","first-page":"27","article-title":"Sodium bicarbonate to improve physical function in patients over 60 years with advanced chronic kidney disease","volume":"24","author":"Witham","year":"2020","journal-title":"the BiCARB RCT"},{"issue":"1","key":"10.1053\/j.ackd.2022.05.002_bib59","doi-asserted-by":"crossref","first-page":"26","DOI":"10.2215\/CJN.07300717","article-title":"Randomized, controlled trial of TRC101 to increase serum bicarbonate in patients with CKD","volume":"13","author":"Bushinsky","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10179","key":"10.1053\/j.ackd.2022.05.002_bib60","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(18)32562-5","article-title":"Veverimer versus placebo in patients with metabolic acidosis associated with chronic kidney disease: a multicentre, randomised, double-blind, controlled, phase 3 trial","volume":"393","author":"Wesson","year":"2019","journal-title":"Lancet"},{"issue":"10196","key":"10.1053\/j.ackd.2022.05.002_bib61","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S0140-6736(19)31388-1","article-title":"Long-term safety and efficacy of veverimer in patients with metabolic acidosis in chronic kidney disease: a multicentre, randomised, blinded, placebo-controlled, 40-week extension","volume":"394","author":"Wesson","year":"2019","journal-title":"Lancet"}],"container-title":["Advances in Chronic Kidney Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559522000970?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559522000970?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T07:05:14Z","timestamp":1761548714000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1548559522000970"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":61,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S1548559522000970"],"URL":"https:\/\/doi.org\/10.1053\/j.ackd.2022.05.002","relation":{},"ISSN":["1548-5595"],"issn-type":[{"value":"1548-5595","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Importance of Metabolic Acidosis as a Health Risk in Chronic Kidney Disease","name":"articletitle","label":"Article Title"},{"value":"Advances in Chronic Kidney Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ackd.2022.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}